isradipine has been researched along with Bone Loss, Osteoclastic in 1 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The decrease in bone resorption correlated with an increase in [Ca2+]i." | 1.29 | Direct effect of calcium channel antagonists on osteoclast function: alterations in bone resorption and intracellular calcium concentrations. ( Fitzpatrick, LA; Maercklein, PB; Ritchie, CK, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ritchie, CK | 1 |
| Maercklein, PB | 1 |
| Fitzpatrick, LA | 1 |
1 other study available for isradipine and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Direct effect of calcium channel antagonists on osteoclast function: alterations in bone resorption and intracellular calcium concentrations.
Topics: Animals; Bone Resorption; Calcium; Calcium Channel Blockers; Cells, Cultured; Intracellular Membrane | 1994 |